TLDR Polymarket and Kalshi now offer contracts tied to health decisions, including CDC vaccine changes. A Johns Hopkins expert says FDA and trial markets reward people who leak private information. Critics warn trial participants and drug companies could act to sway results. Kalshi says clinical trial markets could make drug development more transparent. Kalshi faces a tribal lawsuit, and Polymarket has announced large layoffs.
Polymarket and Kalshi now let users trade contracts tied to health decisions. Users can bet on events such as whether the US Centers for Disease Control and Prevention (CDC) will change its vaccine recommendations.
The markets also cover Food and Drug Administration (FDA) decisions and clinical trial outcomes. Some health experts say this gives people who hold private information a new way to profit from it.
Insider Information Worries
Matthew Eisenberg, professor and chair of health policy and management at the Johns Hopkins Bloomberg School of Public Health, said he was not surprised by the move. Both platforms list contracts on almost any event with an outcome that can be checked.
He said markets on FDA decisions and trial results give a reason to cash in to people with access to confidential details. This group includes agency reviewers, trial investigators and legislative staff.
Platforms may add safeguards, such as checking a user’s employer when they sign up. Still, he said the bigger risk may be people leaking insider information for money, rather than bribery.
Critics also warn the markets could change how drugs are tested. Trial participants might change their behavior on purpose to affect results.
Drug companies could also shift the timing of trials to move predictions. Either case could affect how new medicines are studied and approved.
Kalshi spokesperson Dani Lever offered a different view. Lever said markets on clinical trials